The process of tumor growth and proliferation requires the formation of neovascularization, in which VEGF plays an important role. The VEGF family includes several related molecules such as VEGF-A, VEGF-B, VEGF-C and VEGF-D. Among them, the most important in tumor neovascularization is VEGF-A. This factor promotes the growth and proliferation of vascular endothelial cells and binds to the growth factor receptors produced by vascular endothelial cells to activate downstream signaling pathways, ultimately promoting neovascularization. Bevacizumab AVASTIN, a recombinant humanized monoclonal antibody that binds to vascular endothelial growth factor (VEGF), binds to VEGF-A and blocks its interaction with the VEGF receptor, acting as an anti-new blood vessel formation and thus inhibiting tumor growth. Clinical trials have demonstrated that the combination of bevacizumab and chemotherapy can significantly improve the efficiency of metastatic colorectal cancer and prolong the progression-free survival and overall survival of patients. As a result, the US FDA approved it for clinical use in 2004, making it the first targeted VEGF drug to be used in the clinic. Several subsequent studies have shown that bevacizumab combined with chemotherapy is effective in a variety of solid tumors, including non-small cell lung cancer, metastatic breast cancer and metastatic kidney cancer. Currently, the registration clinical trial of bevacizumab in China has been completed and it is expected to be approved for marketing in China in 2010. Although numerous clinical studies abroad have demonstrated the good safety of bevacizumab in clinical use, with low incidence of serious adverse events and no overlap of related adverse reactions with cytotoxic drugs. However, as the associated adverse events unique to targeted VEGF drugs, such as bleeding, gastrointestinal perforation, and arterial thrombosis, these serious adverse events caused by bevacizumab, although low in incidence, may be fatal for a very small number of patients. In order to enable Chinese medical oncologists to recognize the adverse effects of bevacizumab at an early stage and better prepare for the use of bevacizumab, this article reviews the occurrence, possible mechanisms, risk factors and clinical management measures of the related adverse effects after the clinical application of bevacizumab in China and abroad.